Futibatinib 4 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 4 mg

Reference Brands: Lytgobi (USA)

Category: Oncology Cancer Care

Futibatinib is a Oncology Cancer Care product available as Tablets in strengths 4 mg. It corresponds to the reference brand Lytgobi (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Futibatinib, marketed under the brand name Lytgobi, is an oral anti-cancer medication used for the treatment of adults with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma. It is specifically indicated for patients whose tumors have fibroblast growth factor receptor 2 (FGFR2) gene fusions or other FGFR2 structural alterations and who have previously received systemic therapy.

Futibatinib is a potent tyrosine kinase inhibitor that works by irreversibly blocking FGFR signaling pathways involved in cancer cell growth, survival, and angiogenesis. By inhibiting FGFR activity, Futibatinib helps slow tumor progression and may induce cancer cell death in FGFR-driven tumors. Its irreversible binding mechanism allows sustained inhibition of FGFR, making it effective even in cases where resistance to other FGFR inhibitors may develop.

Administered orally in tablet form, Futibatinib offers a targeted treatment option for patients with limited therapeutic alternatives. In addition to cholangiocarcinoma, Futibatinib is being studied in clinical trials for its potential use in other FGFR-altered malignancies. Lytgobi represents an important advancement in precision oncology, providing targeted therapy based on specific genetic alterations.